01Apr 2023
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence

Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence

The study aimed to estimate the cost-effectiveness of using SGLT2 inhibitors in the management of type 2 diabetes mellitus, taking into account their cardio- and reno-protective effects. The study found that introducing SGLT2 inhibitors was cost-effective for all subpopulations on treatment pathways reflecting the NG28-2022 guidelines, becoming cost-saving between 2 and 16 years post-initiation. Using SGLT2 inhibitors resulted in lower predicted lifetime costs than pathways reflecting the NG28-2015 guidelines and incremental gains in quality-adjusted life years, leading to dominance for the updated NG28-2022 guidance in all scenarios.

  • #endo-diabetology

Like

Save

Share